Is osimertinib chemotherapy or targeted therapy?

Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It is a typical targeted therapy drug, not a chemotherapy drug in the traditional sense. It is specifically used to treat patients with non-small cell lung cancer (NSCLC) carrying EGFR sensitive mutations and T790M drug-resistant mutations. It precisely targets cancer cell mutation sites and blocks their signaling pathways, thereby inhibiting tumor growth and spread.

Unlike traditional chemotherapy drugs, osimertinib’s mechanism of action is more selective. Chemotherapy drugs usually kill rapidly dividing cells, so they not only attack cancer cells, but also damage normal dividing cells, such as bone marrow cells, hair follicle cells, and gastrointestinal mucosal cells, leading to obvious side effects such as hair loss, nausea, and bone marrow suppression. Osimertinib mainly targets EGFR mutated tumor cells, has relatively little impact on normal cells, is well tolerated, and has relatively mild side effects.

Osimertinib has a wide range of clinical applications. It can be used as a first-line treatment for EGFR mutated advanced lung cancer, and is also commonly used in patients with T790M resistance mutations after early EGFR-TKI treatment. In multiple large clinical trials, osimertinib has demonstrated better progression-free survival and overall survival than first- or second-generation EGFR-TKIs, especially in the control of brain metastases.

In short, osimertinib is one of the representative drugs of modern molecular targeted therapy. Different from the non-specific cytotoxic killing of traditional chemotherapy, it uses targeting mutant proteins as its core mechanism to provide a more precise and personalized anti-cancer plan. For patients who meet the EGFR mutation criteria, osimertinib not only has significant efficacy, but also has less impact on quality of life. It has become an important drug choice in the targeted treatment of non-small cell lung cancer.

Reference materials:https://go.drugbank.com/drugs/DB09330